Dyne Therapeutics (NASDAQ:DYN) PT Raised to $42.00 at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Chardan Capital from $31.00 to $42.00 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued reports about the company. Stifel Nicolaus increased their price […]

Related Keywords

United States ,Jasonp Rhodes ,Piper Sandler ,Stifel Nicolaus ,Zurcher Kantonalbank Zurich Cantonalbank ,Jefferies Financial Group ,Securities Exchange Commission ,Raymond James Associates ,Dyne Therapeutics Company Profile ,Dyne Therapeutics Inc ,York Mellon Corp ,Td Asset Management Inc ,Allspring Global Investments Holdings ,Dyne Therapeutics ,Free Report ,Chardan Capital ,Marketbeat Ratings ,Moderate Buy ,Therapeutics Stock Down ,Get Free Report ,Director Jason ,Exchange Commission ,New York Mellon Corp ,Kantonalbank Zurich Cantonalbank ,Management Inc ,Global Investments Holdings ,Dyne Therapeutics Daily ,